Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines by Lien Vandenberk et al.
January 2016 | Volume 6 | Article 6631
Review
published: 14 January 2016
doi: 10.3389/fimmu.2015.00663
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Fabrizio Mattei, 
Istituto Superiore di Sanità, Italy
Reviewed by: 
Zong Sheng Guo, 




Lien Vandenberk  
lien.vandenberk@med.kuleuven.be; 
Stefaan W. Van Gool  
vangool@iozk.de
Specialty section: 
This article was submitted to Tumor 
Immunity, 







Van Woensel M, Riva M and 
Van Gool SW (2016) Exploiting the 
Immunogenic Potential of Cancer 
Cells for Improved Dendritic Cell 
Vaccines. 
Front. Immunol. 6:663. 
doi: 10.3389/fimmu.2015.00663
exploiting the immunogenic Potential 
of Cancer Cells for improved 
Dendritic Cell vaccines
Lien Vandenberk1* , Jochen Belmans1 , Matthias Van Woensel2,3 , Matteo Riva1,4 and 
Stefaan W. Van Gool1,5,6*
1 Laboratory of Pediatric Immunology, Department of Immunology and Microbiology, KU Leuven University of Leuven, 
Leuven, Belgium, 2 Laboratory of Experimental and Neuroanatomy, Department of Neurosciences, KU Leuven University of 
Leuven, Leuven, Belgium, 3 Laboratory of Pharmaceutics and Biopharmaceutics, Université Libre de Bruxelles, Brussels, 
Belgium, 4 Department of Neurosurgery, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, 5 Kinderklinik, 
RWTH, Aachen, Germany, 6 Immunologic-Oncologic Centre Cologne (IOZK), Köln, Germany
Cancer immunotherapy is currently the hottest topic in the oncology field, owing predom-
inantly to the discovery of immune checkpoint blockers. These promising antibodies and 
their attractive combinatorial features have initiated the revival of other effective immuno-
therapies, such as dendritic cell (DC) vaccinations. Although DC-based immunotherapy 
can induce objective clinical and immunological responses in several tumor types, the 
immunogenic potential of this monotherapy is still considered suboptimal. Hence, focus 
should be directed on potentiating its immunogenicity by making step-by-step protocol 
innovations to obtain next-generation Th1-driving DC vaccines. We review some of the 
latest developments in the DC vaccination field, with a special emphasis on strategies 
that are applied to obtain a highly immunogenic tumor cell cargo to load and to activate 
the DCs. To this end, we discuss the effects of three immunogenic treatment modalities 
(ultraviolet light, oxidizing treatments, and heat shock) and five potent inducers of immu-
nogenic cell death [radiotherapy, shikonin, high-hydrostatic pressure, oncolytic viruses, 
and (hypericin-based) photodynamic therapy] on DC biology and their application in 
DC-based immunotherapy in preclinical as well as clinical settings.
Keywords: immunotherapy, dendritic cell vaccines, immunogenic cell death, antitumor immunity, tumor lysate, 
immunogenicity
iNTRODUCTiON
Cancer immunotherapy has gained considerable momentum over the past 5 years, owing predomi-
nantly to the discovery of immune checkpoint inhibitors. These inhibitors are designed to release 
the brakes of the immune system that under physiological conditions prevent auto-immunity 
by negatively regulating cytotoxic T lymphocyte (CTL) function. Following the FDA approval 
of the anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody (mAb) 
Abbreviations: CD, cluster of differentiation; CRT, calreticulin; CVB3, coxsacievirus B3; DAMP, damage-associated molecular 
pattern; DC, dendritic cell; ER, endoplasmic reticulum; HHP, high-hydrostatic pressure; HMGB1, high-mobility group box 
1; HSP, heat shock protein; Hyp, hypericin; ICD, immunogenic cell death; NDV, Newcastle disease virus; OAMP, oxidation- 
associated molecular pattern; PDT, photodynamic therapy; ROS, reactive oxygen species; TLR, Toll-like receptor; UV, ultraviolet.
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ipilimumab (Yervoy) in 2011 for the treatment of metastatic 
melanoma patients (1), two mAbs targeting programed death 
(PD)-1 receptor signaling (nivolumab and pembrolizumab) 
have very recently joined the list of FDA-approved checkpoint 
blockers (respectively, for the treatment of metastatic squamous 
non-small cell lung cancer and relapsed/refractory melanoma 
patients) (2, 3).
However, the primary goal of cancer immunotherapy is to 
activate the immune system in cancer patients. This requires the 
induction of tumor-specific T-cell-mediated antitumor immu-
nity. Checkpoint blockers are only able to abrogate the brakes 
of a functioning antitumoral immune response, implying that 
only patients who have pre-existing tumor-specific T cells will 
benefit most from checkpoint blockade. This is evidenced by the 
observation that ipilimumab may be more effective in patients 
who have pre-existing, albeit ineffective, antitumor immune 
responses (4). Hence, combining immune checkpoint blockade 
with immunotherapeutic strategies that prime tumor-specific 
T cell responses might be an attractive and even synergistic 
approach. This relatively new paradigm has lead to the revival 
of existing, and to date disappointing (as monotherapies), active 
immunotherapeutic treatment modalities. One promising strat-
egy to induce priming of tumor-specific T cells is dendritic cell 
(DC)-based immunotherapy.
Dendritic cells are positioned at the crucial interface 
between the innate and adaptive immune system as powerful 
antigen-presenting cells capable of inducing antigen-specific T 
cell responses (5). Therefore, they are the most frequently used 
cellular adjuvant in clinical trials. Since the publication of the 
first DC vaccination trial in melanoma patients in 1995, the 
promise of DC immunotherapy is underlined by numerous 
clinical trials, frequently showing survival benefit in comparison 
to non-DC control groups (6–8). Despite the fact that most DC 
vaccination trials differ in several vaccine parameters (i.e., site 
and frequency of injection, nature of the DCs, choice of antigen), 
DC vaccination as a monotherapy is considered safe and rarely 
associates with immune-related toxicity. This is in sharp contrast 
with the use of mAbs or cytokine therapies. Ipilumumab has, 
for instance, been shown to induce immune-related serious 
adverse events in up to one-third of treated melanoma patients 
(1). The FDA approval of Sipuleucel-T (Provenge), an autologous 
DC-enriched vaccine for hormone-resistant metastatic prostate 
cancer, in 2010 is really considered as a milestone in the vac-
cination community (9). After 15  years of extensive clinical 
research, Sipileucel-T became the first cellular immunotherapy 
ever that received FDA approval, providing compelling evi-
dence for the substantial socio-economic impact of DC-based 
immunotherapy. DC vaccinations have most often been applied 
in patients with melanoma, prostate cancer, high-grade glioma, 
and renal cell cancer. Although promising objective responses 
and tumor-specific T cell responses have been observed in all 
these cancer-types (providing proof-of-principle for DC-based 
immunotherapy), the clinical success of this treatment is still 
considered suboptimal (6). This poor clinical efficacy can in part 
be attributed to the severe tumor-induced immune suppression 
and the selection of patients with advanced disease status and 
poor survival prognostics (6, 10–12).
There is a consensus in the field that step-by-step optimization 
and standardization of the production process of DC vaccines, 
to obtain a Th1-driven immune response, might enhance their 
clinical efficacy (13). In this review, we address some recent DC 
vaccine adaptations that impact DC biology. Combining these 
novel insights might bring us closer to an ideal DC vaccine 
product that can trigger potent CTL- and Th1-driven antitumor 
immunity.
One factor requiring more attention in this production 
process is the immunogenicity of the dying or dead cancer cells 
used to load the DCs. It has been shown in multiple preclinical 
cancer models that the methodology used to prepare the tumor 
cell cargo can influence the in  vivo immunogenic potential of 
loaded DC vaccines (14–19). Different treatment modalities 
have been described to enhance the immunogenicity of cancer 
cells in the context of DC vaccines. These treatments can 
potentiate antitumor immunity by inducing immune responses 
against tumor neo-antigens and/or by selectively increasing the 
exposure/release of particular damage-associated molecular pat-
terns (DAMPs) that can trigger the innate immune system (14, 
17–19). The emergence of the concept of immunogenic cell death 
(ICD) might even further improve the immunogenic potential 
of DC vaccines. Cancer cells undergoing ICD have been shown 
to exhibit excellent immunostimulatory capacity owing to the 
spatiotemporally defined emission of a series of critical DAMPs 
acting as potent danger signals (20, 21). Thus far, three DAMPs 
have been attributed a crucial role in the immunogenic potential 
of nearly all ICD inducers: the surface-exposed “eat me” signal 
calreticulin (ecto-CRT), the “find me” signal ATP and passively 
released high-mobility group box 1 (HMGB1) (21). Moreover, 
ICD-experiencing cancer cells have been shown in various mouse 
models to act as very potent Th1-driving anticancer vaccines, 
already in the absence of any adjuvants (21, 22). The ability to 
reject tumors in syngeneic mice after vaccination with cancer 
cells (of the same type) undergoing ICD is a crucial hallmark of 
ICD, in addition to the molecular DAMP signature (21).
Here, we review the effects of three frequently used immuno-
genic modalities and four potent ICD inducers on DC biology and 
their application in DC vaccines in preclinical as well as clinical 
settings (Tables 1 and 2). Moreover, we discuss the rationale for 
combining different cell death-inducing regimens to enhance the 
immunogenic potential of DC vaccines and to ensure the clinical 
relevance of the vaccine product.
THe iMPACT OF DC BiOLOGY ON THe 
eFFiCACY OF DC vACCiNeS
Over the past years, different DC vaccine parameters have been 
shown to impact the clinical effectiveness of DC vaccinations. In 
the next section, we will elaborate on some promising adaptations 
of the DC preparation protocol.
Given the labor-intensive ex vivo culturing protocol of mono-
cyte-derived DCs and inspired by the results of the Provenge study, 
several groups are currently exploiting the use of blood-isolated 
naturally circulating DCs (76–78). In this context, De Vries et al. 
evaluated the use of antigen-loaded purified plasmacytoid DCs 
TABLe 1 | A list of prominent enhancers of immunogenicity and iCD inducers applied in DC vaccine setups and their associations with DAMPs and DC 
biology.
Treatment modality Associated DAMPs effect on DC biology
immunogenic treatment modality
UV irradiation Pre-apoptotic ecto-CRT (23); post-apoptotic passive 
release of HSP70 and HMGB1 (24); mutation-induced 
neo-antigens (25)
Efficient engulfment; phenotypic maturation; increased IL-12 secretion; 
stimulate the polarization of T cells toward CTLs (19, 24, 26, 27)
Oxidation-inducing modalities 
(HOCl/H2O2 treatment or 
freeze–thaw cycles followed 
by X-ray irradiation)
OAMPs (reactive protein carbonyls, peroxidized 
phospholipids, oxidized low-density lipoprotein) (14, 18, 
28–30); carbonylated protein products presented as 
neo-antigens (30, 31)
Efficient antigen uptake and presentation; induction of IL-12; increased 
in vivo induction of tumor-reactive T cells (14); induction of Th1- and CTL-
driven antitumor immunity (18)
Heat shock Passive release of heat shock proteins like 
HSP60/70/90 (17, 32); passive release of HMGB1 (33); 
increased expression of tumor-specific antigens (34)
Upregulation of DC maturation markers (CD40, CD80, and CD86) and 
induction of IL-12 (32); enhanced priming of CTL responses (17, 34)
inducers of immunogenic cell death
Radiotherapy Pre-apoptotic exposure of ecto-CRT (23, 24, 35); 
early/mid-apoptotic exposure of ecto-HSP70 (36); 
post-apoptotic passive release of HMGB1 (33, 35); 
mutation-induced neo-antigens (25)
Efficient phagocytosis and enhanced phenotypic maturation (37); increased 
infiltration in the tumor environment (38, 39); enhanced stimulation of 
antigen-specific CTL responses (40)
Shikonin Early/mid-apoptotic induction of ecto-HSP70, ecto-
CRT and ecto-GRP78 (an inducer of pro-tumorigenic 
effects) (41)
Increased phenotypic (CD40high, CD80high, CD86high) and functional 
maturation (IL-12p70high, TGF-βhigh, IL-6high, IL-23low) but only in combination 
with LPS; increased capacity to induce Th1 and Th17 differentiation (41)
High-hydrostatic pressure Early/mid-apoptotic exposure of ecto-HSP70, ecto-
HSP90, ecto-CRT; pre-apoptotic ATP release; post-
apoptotic passive release of HMGB1, HSP70/90, and 
CRT (42)
Efficient phagocytosis; enhanced phenotypic and functional maturation; 
induction of antigen-specific T cells without inducing Tregs (42)
Oncolytic viruses CVB3 and oncolytic adenovirus: (early-apoptotic) 
exposure of ecto-CRT; (early/mid-apoptotic) secretion 
of ATP and (post-apoptotic) release of HMGB1 (43, 44)
Enhanced expression of CD80/CD86 (44, 46, 47) and CCR7 (44); more 
efficient priming of tumor-specific CD8+ CTL responses (43, 46, 47) and 
Th1 responses (43); increased accumulation in tumor microenvironment 
(43, 44)NDV: early/mid-necroptotic exposure of ecto-CRT and 
post-necroptotic release of HMGB1 (45)
Hypericin-based PDT Pre-apoptotic ecto-CRT, ecto-HSP70 and secreted 
ATP; late apoptotic passive release of HSP70/90, CRT 
and HMGB1; accumulation of OAMPs like protein 
carbonyls (48–50)
Enhanced phagocytosis; phenotypic maturation (CD80high CD86high CD83high 
MHC-IIhigh) and immunogenic functional stimulation (NOhigh IL-10absent IL-6high 
IL-1βhigh IL-12p70medium); clonal expansion of human IFN-γ producing CD4+ 
and CD8+ T cells (49, 53, 54)
Photofrin-based PDT early/mid-apoptotic exposure of CRT, HSP60/70, 
ceramide and S1P; post-apoptotic release of HMGB1 
(51, 52)
Increased phenotypic maturation (CD86high, MHC-IIhigh) and enhanced IL-12 
production (55); increased infiltration in tumor draining lymph nodes after 
peritumoral vaccination (56)
CRT,calreticulin; CTL, cytotoxic T lymphocyte; CVB3, coxsackievirus B3; DAMPs, damage-associated molecular patterns; HMGB1, high-mobility group box-1 protein; HSP, heat 
shock protein; ICD, immunogenic cell death; IFN, interferon; LPS, lipopolysaccharide; NDV, Newcastle disease virus; NO, nitric oxide; OAMPs, oxidation-associated molecular 
patterns; PDT, photodynamic therapy; TGF, transforming growth factor; Treg, regulatory T cell.
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for intranodal injection in melanoma patients (79). This strategy 
was feasible and induced only very mild side effects. In addition, 
the overall survival of vaccinated patients was greatly enhanced as 
compared to historical control patients. However, it still remains 
to be determined whether this strategy is more efficacious than 
monocyte-derived DC vaccine approaches (78). By contrast, 
experiments in the preclinical GL261 high-grade glioma model 
recently showed that vaccination with tumor antigen-loaded 
myeloid DCs resulted in more robust Th1 responses and a 
stronger survival benefit as compared to mice vaccinated with 
their plasmacytoid counterparts (80).
In view of their strong potential to stimulate cytotoxic T 
cell responses, several groups are currently exploring the use of 
Langerhans cell-like DCs as sources for DC vaccines (81–83). 
These so-called IL-15 DCs can be derived from CD14+ mono-
cytes by culturing them with IL-15 (instead of the standard IL-4). 
Recently, it has been shown that in comparison to IL-4 DCs, these 
cells have an increased capacity to stimulate antitumor natural 
killer (NK) cell cytotoxicity in a contact- and IL-15-dependent 
manner (84). NK cells are increasingly being recognized as 
crucial contributors to antitumor immunity, especially in DC 
vaccination setups (85, 86). Three clinical trials are currently 
evaluating these Langerhans cell-type DCs in melanoma patients 
(NCT00700167, NCT 01456104, and NCT01189383).
Targeting cancer stem cells is another promising development, 
particularly in the setting of glioma (87). Glioma stem cells can 
foster tumor growth, radio- and chemotherapy-resistance, and 
local immunosuppression in the tumor microenvironment (87, 
88). Furthermore, glioma stem cells may express higher levels of 
tumor-associated antigens and MHC complex molecules as com-
pared to non-stem cells (89, 90). A preclinical study in a rodent 
orthotopic glioblastoma model has shown that DC vaccines 
loaded with neuropsheres enriched in cancer stem cells could 
induce more immunoreactivity and survival benefit as compared 
TABLe 2 | A list of preclinical tumor models and clinical studies for evaluation of the in vivo potency of DC vaccines loaded with immunogenically killed 
tumor cells.
Treatment modality Preclinical experience in DC vaccine settings Clinical experience in DC vaccine settings
immunogenic treatment modalities
UV irradiation B16 melanoma in C57BL/6 – curative immunizations 
(19); ID8-ova ovarian carcinoma model in C57BL/6 
mice – weekly curative immunizations (14)
Only in combination with γ-irradiation and heat shock in B-cell 
lymphoma patients (57)
Oxidation-inducing modalities 
(HOCl/H2O2 treatment or 
freeze–thaw cycles followed 
by X-ray irradiation)
ID8-ova ovarian carcinoma model in C57BL/6 
mice – weekly curative immunizations (14); orthotopic 
GL261 high-grade glioma model in C57BL/6 mice – both 
prophylactic and curative vaccination settings induced 
a pro-inflammatory shift in the brain-infiltrating immune 
cells and the protein carbonyl content in the tumor lysate 
positively correlated with tumor rejection (18)
Freeze–thaw cycles in combination with high-dose irradiation: often 
reported in clinical trials involving high-grade glioma and melanoma 
patients (8, 58–66)
HOCl: pilot study in five recurrent ovarian cancer patients demonstrated 
potent T cell responses against tumor antigens, decreased circulating 
Treg levels, and serum IL-10 levels and two patients experienced 
durable PFS responses of ≥24 months (14)
Heat shock PANCO2 pancreatic cancer model in C57BL/6 
mice – curative vaccinations (17); in combination with 30 Gy 
irradiation in B16-ova model in C57BL/6 mice – prophylactic 
vaccinations (16)
Non-randomized trial in newly diagnosed glioblastoma patients 
(67): significantly improved tumor control rates and survival rates in 
DC vaccine group than in control group; increased proportions of 
peripheral CD4+ and CD8+ T cells post vaccination compared to 
control group; in combination with other cell killing modalities in B-cell 
lymphoma and melanoma patients (57, 68)
inducers of immunogenic cell death
Radiotherapy B16 melanoma in C57BL/6 – prophylactic immunization 
model with critical involvement of CD4+ and CD8+ T cells 
(15, 37); E.G7 (SCCVII) in C57BL/6 – curative vaccination 
model (40)
Radiotherapy as a single intervention: multiple clinical trials in 
melanoma patients (8) and two clinical trials in high-grade glioma 
patients (69, 70). This study by Cho and colleagues reported a survival 
advantage of more than 15 months in the vaccinated glioblastoma 
patients in comparison to the control group (receiving conventional 
treatment)
Radiotherapy as part of an ICD-inducing cell death protocol in B-cell 
lymphoma patients (57)
Shikonin B16 melanoma in C57BL/6 – curative immunization model 
with strong induction of CTL responses (41)
Not available
High-hydrostatic pressure Preclinical experiments are currently ongoing (71) Multiple clinical trials are initiated involving prostate and ovarian cancer 
patients (71)
Oncolytic viruses Not applied as ICD-based DC vaccines yet; curative 
combination of intratumoral oncolytic virus treatment and 
peripheral DC vaccination in B16 melanoma (C57BL/6) 
(72) and in subcutaneous CMT64 or KNL205 tumors (in 
C57BL/6 mice and DBA/2 DREG mice, respectively) (73)
Case report of breast cancer patient treated with combination of local 
hyperthermia, intravenously administered NDV and intradermal DC 
vaccines loaded with NDV-oncolysate (74)
Hypericin-based PDT Not available Not available
Photofrin-based PDT In vivo photofrin-PDT treatment in combination with curative 
DC vaccination in C-26 colon carcinoma (BALB/c) (75); 
curative vaccinations with DCs charged with PDT-induced 
tumor lysate in EMT6, Renca and 4T1 non-orthotopic tumor 
modes (BALB/c), induction of CTL and Th1 responses
Not available
CRT, calreticulin; CTL, cytotoxic T lymphocyte; DC, dendritic cell; ICD, immunogenic cell death; NDV, Newcastle disease virus; PDT, photodynamic therapy; PFS, progression-free 
survival.
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order to generate a strong T cell response. In view of this finding, 
the route of administration is another vaccine parameter that can 
influence the homing of the injected DCs to the lymph nodes. 
In the context of prostate cancer and renal cell carcinoma it has 
been shown that vaccination routes with access to the draining 
lymph nodes (intradermal/intranodal/intralymphatic/subcu-
taneous) resulted in better clinical response rates as compared 
to intravenous injection (93). In melanoma patients, a direct 
comparison between intradermal vaccination and intranodal 
vaccination concluded that, although more DCs reached the 
lymph nodes after intranodal vaccination, the melanoma-specific 
T cells induced by intradermal vaccination were more functional 
to DCs loaded with GL261 cells grown under standard condi-
tions (91). Currently there are four clinical trials ongoing in high-
grade glioma patients evaluating this approach (NCT00890032, 
NCT00846456, NCT01171469, and NCT01567202).
With regard to the DC maturation status of the vaccine 
product, a phase I/II clinical trial in metastatic melanoma 
patients has confirmed the superiority of mature antigen-loaded 
DCs to elicit immunological responses as compared to their 
immature counterparts (92). This finding was further substanti-
ated in patients diagnosed with prostate cancer and recurrent 
high-grade glioma (93, 94). Hence, DCs need to express potent 
costimulatory molecules and lymph node homing receptors in 
FiGURe 1 | A schematic representation of immunogenic DC vaccines. Cancer cells show enhanced immunogenicity upon treatment with UV irradiation, 
oxidizing treaments, and heat shock, characterized by the release of particular danger signals and the (increased) production of tumor (neo-)antigens. Upon loading 
onto DCs, DCs undergo enhanced phagocytosis and antigen uptake and show phenotypic and partial functional maturation. Upon in vivo immunization, these DC 
vaccines elicit Th1- and cytotoxic T lymphocyte (CTL)-driven tumor rejection.
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(95). Furthermore, the frequency of vaccination can also influ-
ence the vaccine’s immunogenicity. Our group has shown in a 
cohort-comparison trial involving relapsed high-grade glioma 
patients that shortening the interval between the four inducer DC 
vaccines improved the progression-free survival curves (58, 96).
Another variable that has been systematically studied is the 
cytokine cocktail that is applied to mature the DCs. The cur-
rent gold standard cocktail for DC maturation contains TNF-α, 
IL-1β, IL-6, and PGE2 (97, 98). Although this cocktail upregulates 
DC maturation markers and the lymph node homing receptor 
CCR7, IL-12 production by DCs could not be evoked (97, 
98). Nevertheless, IL-12 is a critical Th1-driving cytokine and 
DC-derived IL-12 has been shown to associate with improved 
survival in DC vaccinated high-grade glioma and melanoma 
patients (99, 100). Recently, a novel cytokine cocktail, includ-
ing TNF-α, IL-1β, poly-I:C, IFN-α, and IFN-γ, was introduced 
(101, 102). The type 1-polarized DCs obtained with this cocktail 
produced high levels of IL-12 and could induce strong tumor-
antigen-specific CTL responses through enhanced induction of 
CXCL10 (99). In addition, CD40-ligand (CD40L) stimulation of 
DCs has been used to mature DCs in clinical trials (100, 103). 
Binding of CD40 on DCs to CD40L on CD4+ helper T cells 
licenses DCs and enables them to prime CD8+ effector T cells.
A final major determinant of the vaccine immunogenicity is 
the choice of antigen to load the DCs. Two main approaches can be 
applied: loading with selected tumor antigens (tumor-associated 
antigens or tumor-specific antigens) and loading with whole 
tumor cell preparations (13). The former strategy enables easier 
immune monitoring, has a lower risk of inducing auto-immunity, 
and can provide “off-the-shelf ” availability of the antigenic cargo. 
Whole tumor cell-based DC vaccines, on the other hand, are not 
HLA-type dependent, have a reduced risk of inducing immune-
escape variants, and can elicit immunity against multiple tumor 
antigens. Meta-analytical data provided by Neller et  al. have 
demonstrated enhanced clinical efficacy in several tumor types of 
DCs loaded with whole tumor lysate as compared to DCs pulsed 
with defined tumor antigens (104). This finding was recently also 
substantiated in high-grade glioma patients, although this study 
was not set-up to compare survival parameters (105).
TOwARD A MORe iMMUNOGeNiC 
TUMOR CeLL CARGO
The majority of clinical trials that apply autologous whole tumor 
lysate to load DC vaccines report the straightforward use of mul-
tiple freeze–thaw cycles to induce primary necrosis of cancer cells 
(8, 93). Freeze–thaw induced necrosis is, however, considered 
non-immunogenic and has even been shown to inhibit toll-like 
receptor (TLR)-induced maturation and function of DCs (16). 
To this end, many research groups have focused on tackling this 
roadblock by applying immunogenic modalities to induce cell 
death.
immunogenic Treatment Modalities
Tables 1 and 2 list some frequently applied treatment methods 
to enhance the immunogenic potential of the tumor cell cargo 
that is used to load DC vaccines in an ICD-independent manner 
(i.e., these treatments do not meet the molecular and/or cellular 
determinants of ICD). Immunogenic treatment modalities can 
positively impact DC biology by inducing particular DAMPs in 
the dying cancer cells (Table 1). Table 2 lists the preclinical and 
clinical studies that investigated their in vivo potential. Figure 1 
schematically represents the application and the putative modes 
of action of these immunogenic enhancers in the setting of DC 
vaccines.
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Ultraviolet Irradiation
Ultraviolet (UV) light is considered an electromagnetic non-
ionizing radiation with a wavelength between 100 and 400 nm. 
Its immunogenic potential was discovered in 1991 when Begovic 
et al. demonstrated that vaccination of immunocompetent mice 
(but not immunodeficient nude mice) with UV-irradiated 
cancer cells could induce resistance to subsequent rechallenge 
with live tumor cells (23, 106, 107). This antitumor effect was 
crucially mediated by NK cells and CD8+ T cells. UV-treated 
cancer cells are efficiently engulfed by DCs, leading to pheno-
typic maturation and increased IL-12 production (19, 24, 26) 
(Table 1). Moreover, these matured DCs in turn stimulated the 
polarization of T cells toward IFN-γ producing CD8+ T cells 
(24, 26). Of note, human DCs that had ingested UV-irradiated 
apoptotic tumor cells were shown to be more effective in 
generating CD8+ CTLs than DCs pulsed with freeze–thaw 
lysates (27). In addition, immunization with DCs loaded with 
UV-treated tumor cells could elicit effective antitumor thera-
peutic efficacy in a B16 mouse melanoma model, albeit non-
superior to DCs loaded with necrotic freeze–thaw lysate (19) 
(Table 2). The induction of specific DAMPs, such as ecto-CRT, 
and the release of heat shock protein 70 (HSP70) and HMGB1 
determines the immunogenicity of UV irradiation (23, 24, 33) 
(Table 1). Moreover, as UV light is known to affect mainly DNA, 
mutation-induced tumor neo-antigens might also contribute to 
increasing the host antitumor immune response (108). T cells 
reactive against mutated neo-antigens are theoretically less sus-
ceptible to central and peripheral tolerance. Vaccination with 
UV-induced tumor neo-antigens might be particularly useful 
in UV-induced tumors (e.g., cutaneous and uveal melanoma) 
that might share the ex vivo UV-induced tumor neo-antigens. 
Besides, it has previously been shown that immunization of 
tumor-bearing mice with mutated melanoma-derived self-
antigens can elicit efficient cross-reactive CD8+ T cell responses 
against multiple non-mutated epitopes of the tumor protein and 
against the melanoma cells (109). This led to the rejection of 
established poorly immunogenic B16 melanoma tumors (109). 
To the best of our knowledge, there are no reports of clinical 
trials that used UV irradiation as a single treatment for obtain-
ing an antigen source to pulse DC vaccines (Table 2). This is 
probably related to the fact that UV light as a single treatment is 
not able to induce high levels of cancer cell death in the vaccine, 
an absolute requirement for clinical translation.
Oxidation-Inducing Modalities
In recent years, an increasing number of data were published 
concerning the ability of oxidative stress to induce oxidation-
associate molecular patterns (OAMPs), such as reactive protein 
carbonyls and peroxidized phospholipids, which can act as 
DAMPs (28, 29) (Table  1). Protein carbonylation, a surrogate 
indicator of irreversible protein oxidation, has for instance been 
shown to improve cancer cell immunogenicity and to facilitate 
the formation of immunogenic neo-antigens (30, 31).
One prototypical enhancer of oxidation-based immunogenic-
ity is radiotherapy (21, 23). In certain tumor types, such as high-
grade glioma and melanoma, clinical trials that apply autologous 
whole tumor lysate to load DC vaccines report the random use 
of freeze–thaw cycles (to induce necrosis of cancer cells) or a 
combination of freeze–thaw cycles and subsequent high-dose 
γ-irradiation (8, 18) (Table  2). However, from the available 
clinical evidence, it is unclear which of both methodologies has 
superior immunogenic potential. In light of the oxidation-based 
immunogenicity that is associated with radiotherapy, we recently 
demonstrated the superiority of DC vaccines loaded with irradi-
ated freeze–thaw lysate (in comparison to freeze–thaw lysate) in 
terms of survival advantage in a preclinical high-grade glioma 
model (18) (Table  2). This survival advantage was associated 
with an increased tumor infiltration of Th1 cells and CTLs and 
accompanied by a reduced invasion of regulatory cells (Tregs), 
macrophages, and myeloid-derived suppressor cells. Moreover, 
this study revealed a significant positive correlation between the 
level of protein carbonylation – as a measure of the total oxida-
tive content  –  in the tumor lysates used to load the DCs and 
the percentage of mice able to reject the aggressive intracranial 
tumors. Treatment of the tumor lysate with hydrogen peroxide 
(H2O2, a strong oxidant) even induced higher tumor protection 
than irradiated freeze–thaw lysate, warranting the preclinical 
investigation of other strong oxidizing modalities to further 
potentiate the immunogenicity of whole tumor antigen-pulsed 
DC vaccinations.
In line with these results and through a series of elegant 
ex vivo an in  vivo mouse experiments, Chiang et  al. recently 
selected hypochlorous acid (HOCl)-based oxidation (to induce 
primary necrosis of tumor cells) as the method of choice (as 
compared to UVB irradiation and freeze–thaw cycles) for 
preparing whole tumor lysate-loaded DC vaccines in the pre-
clinical ID8 ovarian cancer model (14) (Table 2). Interestingly, 
T  cells stimulated by DCs loaded with HOCl-induced 
oxidatively modified tumor cells were still able to recognize 
non-modified tumor cells, an essential requirement if the cells 
are to exert antitumor activity (30). In a pilot study containing 
five recurrent ovarian cancer patients, these autologous DCs 
loaded with HOCl-oxidized autologous tumor lysate could 
produce high levels of IL-12, elicited strong antigen-specific T 
cell responses and reduced the levels of circulating Tregs and 
serum IL-10 (14). Moreover, two patients experienced durable 
progression-free survival intervals of more than 24  months 
after vaccination (Table 2).
Heat Shock Treatment
Heat shock is a term that is applied when a cell is subjected to a 
temperature that is higher than that of the ideal body temperature 
of the organisms of which the cell is derived. Heat shock can 
induce apoptosis (41–43°C) or necrosis (>43°C) depending on 
the temperature that is applied (110). The immunogenicity of 
heat shock treated cancer cells largely resides within their ability 
to produce HSPs, such as HSP60, HSP70, and HSP90 (17, 32) 
(Table  1). These HSPs can function as chaperones for tumor 
antigens, facilitating their cross-presentation (17). Moreover, 
after recognition by their receptors (CD91, TLR2/4), these 
HSPs can instigate the attraction of neutrophils and monocytes 
and the activation of NK cells and DCs (111). These events are 
crucial for the initiation of tumor-specific immune responses. 
Independent of the induction of HSPs, heat shock treatment 
FiGURe 2 | A schematic representation of immunogenic cell death (iCD)-based DC vaccines. ICD causes cancer cells to emit a spatiotemporally defined 
pattern of danger signals. Upon loading of these ICD-undergoing cancer cells onto DCs, they induce extensive phagocytosis and antigen uptake. Loaded DCs 
show enhanced phenotypic and functional maturation and immunization with these ICD-based DC vaccines instigates Th1-, Th17-, and cytotoxic T lymphocyte 
(CTL)-driven antitumor immunity in vivo.
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has also been shown to upregulate the transcription of specific 
tumor-associated antigens (34).
Co-incubation of heat-stressed apoptotic cancer cells with 
immature DCs resulted in the upregulation of DC maturation 
markers (CD40, CD80, and CD86) and higher IL-12 levels (32) 
(Table  1). Interestingly, splenocytes from mice immunized 
with heat-stressed apoptotic cancer cells got polarized toward 
a Th1 cytokine profile. Furthermore, DCs loaded with heat 
shock stressed melanoma cells can efficiently cross-prime 
tumor-antigen-specific CTLs both in vitro and in vivo (34). Of 
note, direct comparison of heat shock treated tumor lysate with 
freeze–thaw tumor lysate in a DC vaccine setup demonstrated 
a stronger tumor regression in favor of heat shock lysate in a 
mouse model for pancreatic cancer (Table 2). Again, this was 
associated with a stronger priming of tumor-specific CTL 
responses (17).
Dendritic cells loaded with heat shocked cancer cells have 
already been successfully applied in clinical practice in high-
grade glioma patients (Table 2). Jie et al. recently published an 
open labeled non-randomized clinical trial in which 12 newly 
diagnosed glioblastoma patients received conventional therapy 
and 13 patients received additional DC vaccines loaded with 
heat shock treated autologous glioblastoma cells (67). The vac-
cinated patients had a significantly improved overall survival 
and progression-free survival. Interestingly, the proportions of 
peripheral CD4+ T cells, CD8+ T cells, and NK cells were signifi-
cantly higher after DC vaccination in comparison to the control 
group. Moreover, increased levels of IFN-γ, IL-2, and IL-12 were 
measured in the sera of DC vaccinated patients.
All together, these data suggest that an immunogenic treat-
ment of cancer cells can positively impact the potency of DCs 
interacting with them (Figure  1). In light of this finding, the 
relatively new concept of ICD of cancer cells can be considered 
a promising strategy for loading DC-based anticancer vaccines, 
potentially giving rise to a next generation of potent Th1-driving 
DC vaccines (111, 112) (Figure 2).
inducers of immunogenic Cell Death
Immunogenic cell death is a cell death regimen that is associated 
with the spatiotemporally defined emission of immunogenic 
DAMPs that can trigger the immune system (20, 21, 113). ICD 
has been found to depend on the concomitant induction of reac-
tive oxygen species (ROS) and activation of endoplasmatic reticu-
lum (ER) stress (111). Besides the three DAMPs that are most 
crucial for ICD (ecto-CRT, ATP, and HMGB1), other DAMPs 
such as surface-exposed or released HSPs (notably HSP70 and 
HSP90) have also been shown to contribute to the immunogenic 
capacity of ICD inducers (20, 21). The binding of these DAMPs 
to their respective immune receptors (CD91 for HSPs/CRT, 
P2RX7/P2RY2 for ATP, and TLR2/4 for HMGB1/HSP70) leads 
to the recruitment and/or activation of innate immune cells and 
facilitates the uptake of tumor antigens by antigen-presenting 
cells and their cross-presentation to T cells eventually leading to 
IL-1β-, IL-17-, and IFN-γ-dependent tumor eradiation (22). This 
in vivo tumor rejecting capacity induced by dying cancer cells in 
the absence of any adjuvant, is considered as a prerequisite for 
an agent to be termed an ICD inducer. Recently, a classification 
system for ICD inducers was proposed based on whether an ICD 
inducer triggers apoptotic cell death as a consequence of direct 
action at the ER (Type II ICD inducer), or whether it initiates both 
ER stress-dependent danger signaling and apoptosis through 
divergent mechanisms (Type I ICD inducer) (111).
Although the list of ICD inducers is constantly growing (113), 
only few of these immunogenic modalities have been tested in 
order to generate an immunogenic tumor cell cargo to load DC 
vaccines (Tables 1 and 2). Figure 2 schematically represents the 
preparation of ICD-based DC vaccines and their putative modes 
of action.
Radiotherapy
Ionizing X-ray or γ-ray irradiation exerts its anticancer effect 
predominantly via its capacity to induce DNA double-strand 
breaks leading to intrinsic cancer cell apoptosis (114). The idea 
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that radiotherapy could also impact the immune system was 
derived from the observation that radiotherapy could induce 
T-cell-mediated delay of tumor growth in a non-irradiated 
lesion (115). This abscopal (ab-scopus, away from the target) 
effect of radiotherapy was later explained by the ICD-inducing 
capacity (116). Together with anthracyclines, γ-irradiation was 
one of the first treatment modalities identified to induce ICD. 
Although this type I ICD inducer is known to induce ROS, its 
ER stress-inducing capability remains largely unexplored (111). 
The DAMPs that are induced following radiotherapy treatment 
of cancer cells include the exposure of ecto-CRT (23, 24, 35) and 
ecto-HSP70 (36), and the release of HMGB1 (33, 35) (Table 1). 
Irradiated B16 melanoma cells have been shown to be efficiently 
phagocytosed by DCs and to induce phenotypic DC maturation 
(15, 37). In addition, human DCs pulsed with irradiated tumor 
cells could efficiently stimulate antigen-specific CTL responses 
(40) (Table 1). Furthermore, mice immunized with DCs loaded 
with irradiated cancer cells could efficiently suppress tumor 
growth following inoculation with live syngeneic tumor cells in 
multiple preclinical cancer models (15, 40). In this setting, sple-
nocytes from vaccinated animals could efficiently prime CD4+ 
and CD8+ T cells and exerted antigen-specific cytolytic activity 
(15) (Table 2).
Dendritic cell vaccines exposed to irradiated cancer cells 
have also been successfully implemented in clinical practice in 
melanoma and HGG patients (8, 69, 70) (Table 2). Cho et al. have 
shown that the implementation of DC vaccines loaded with irra-
diated autologous tumor cells in the conventional treatment regi-
men of newly diagnosed glioblastoma patients could significantly 
prolong the median overall survival (by more than 15 months) 
as compared to a control group receiving solely conventional 
treatment (69). Interestingly, the group of Di Nicola reported that 
vaccination with DCs loaded with dying autologous tumor cells 
after exposure to a cell death protocol consisting of heat shock, 
γ-ray, and UV ray could elicit clinical responses in 6 out of 18 
relapsed B-cell lymphoma patients (117). Later, they showed 
the impaired ability of the neoplastic cells used to vaccinate 
non-responders to undergo ICD upon exposure to the cell death 
protocol (57). Importantly, they revealed a positive association 
between the extent of CRT and HSP90 surface expression in the 
DC antigenic cargo and the clinical and immunological responses 
achieved (57).
Shikonin
The phytochemical shikonin, a major component of Chinese 
herbal medicine, is known to inhibit proteasome activity. It serves 
multiple biological roles and can be applied as an antibacterial, 
antiviral, anti-inflammatory, and anticancer treatment. The latter 
application has been shown to yield responsiveness in late-stage 
lung cancer patients (118). Apoptotic cell death elicited by this 
type I ICD inducer can be inhibited by anti-oxidants, suggesting 
a role of shikonin-induced ROS (119, 120). The link between shi-
konin treatment and ER stress is not evidenced yet. The ICD that is 
induced in shikonin-treated cancer cells is characterized by the early 
induction of HSP70, HSP90, GRP78, and HMGB1 (41) (Table 1). 
Importantly, shikonin treatment could significantly improve 
the survival of mice bearing P388 leukemia and this antitumor 
effect of shikonin was less pronounced in immunodeficient mice 
(120). Moreover, the tumor lysate from shikonin-treated B16 cells 
could enhance phenotypic and functional DC maturation and 
differentiation of Th1 and Th17 cells, two important features of 
ICD-associated antitumor immunity (41) (Table 1). Additionally, 
curative vaccination of B16 melanoma-inoculated mice with shi-
konin-lysate-loaded DCs could delay tumor growth (41). This was 
associated with increased cytolytic activity of splenocytes on target 
tumor cells (Table 2). Although shikonin is administered to breast 
cancer patients for observational application (NCT01287468), 
clinical experience evaluating shikonin-lysate-loaded DC vaccines 
is unfortunately still lacking (Table 2).
High-Hydrostatic Pressure
High-hydrostatic pressure (HHP) is an established method to 
sterilize pharmaceuticals, human transplants, and food. HHP 
between 100 and 250 megapascal (MPa) has been shown to induce 
apoptosis of murine and human (cancer) cells (121–123). While 
DNA damage does not seem to be induced by HHP <1000 MPa, 
HHP can inhibit enzymatic functions and the synthesis of cellular 
proteins (122). Increased ROS production was detected in HHP-
treated cancer cell lines and ER stress was evidenced by the rapid 
phosphorylation of eIF2α (42).
The anticancer activity of HHP was already demonstrated 
more than four decades ago in bladder cancer patients (124). Later, 
preclinical experiments demonstrated in vivo immunogenicity of 
HHP-treated cancer cells in the B16 melanoma model and the 
3LL-D122 lung metastasis model (125, 126). Subsequently, it was 
shown that HHP-treated mammalian cancer cell lines undergo-
ing apoptosis can release HSP70 and HMGB1, while retaining 
their immunogenicity in vivo (127). Very recently, Fucikova and 
colleagues have shown the ability of HHP to induce prototypi-
cal ICD in human prostate and ovarian cancer cell lines and in 
acute leukemia cells (42). HHP treatment induced the rapid 
expression of ecto-HSP70, ecto-HSP90, and ecto-CRT and the 
release of HMGB1 and ATP (Table 1). Interestingly, HHP-treated 
cancer cells were rapidly phagocytosed by DCs and induced the 
upregulation of CD83, CD86, and HLA-DR, and the release of 
pro-inflammatory cytokines (Table 1). This led to the stimulation 
of high numbers of tumor-specific T cells without inducing Tregs. 
Hence, all ICD-associated molecular criteria are fulfilled for 
HHP. This group is currently testing the in vivo immunogenicity 
of HHP killed tumor cells in prophylactic and curative murine 
vaccination settings (Table  2). Moreover, they have initiated 
multiple clinical trials to evaluate the potential of DC vaccines 
loaded with HHP-treated cancer cells in ovarian and prostate 
cancer patients (71).
Oncolytic Viruses
Oncolytic viruses are self-replicating, tumor selective virus 
strains that can directly lyse tumor cells. Over the past few years, 
a new oncolytic paradigm has risen; entailing that, rather than 
utilizing oncolytic viruses solely for direct tumor eradication, the 
cell death they induce should be accompanied by the elicitation 
of antitumor immune responses to maximize their therapeutic 
efficacy (128). One way in which these oncolytic viruses can fulfill 
this oncolytic paradigm is by inducing ICD (128).
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Thus far, three oncolytic virus strains can meet the molecular 
requirements of ICD; coxsackievirus B3 (CVB3), oncolytic 
adenovirus and Newcastle disease virus (NDV) (Table 1) (113). 
Infection of tumor cells with these viruses causes the production 
of viral envelop proteins that induce ER stress by overloading the 
ER. Hence, all three virus strains can be considered type II ICD 
inducers (113). While CVB3 and oncolytic adenoviruses induce 
the surface expression of CRT, followed by the release of ATP and 
the passive release of HMGB1 in apoptotic tumor cells (in non-
small cell lung carcinoma and adenocarcinoma cells, respectively) 
(43, 44), NDV induces necroptosis accompanied by the surface 
exposure of ATP and the post-necroptotic release of HMGB1 in 
GL261 glioma cells, with no contribution of ATP (Table 1) (45). 
In addition, NDV-infected GL261 cells upregulated the expres-
sion of the PMEL17 tumor antigen (45).
Intratumoral administration of CVB3 in nude mice resulted in 
the marked infiltration of NK cells, macrophages, granulocytes, 
and mature DCs into the tumor tissue (Table  1) (44). Tumor-
infiltrating DCs expressed significantly higher levels of costimu-
latory molecules CD80 and CD86, as well as the lymph node 
homing receptor CCR7 (44). CD40-ligand encoding oncolytic 
adenoviruses have also been shown to facilitate the recruitment 
of DCs to the tumor tissue, this way entailing efficient Th1 and 
CD8+ CTL responses (Table  1) (43). Measles virus is another 
oncolytic virus that requires further investigation. Although 
extensive analysis of in vitro ICD determinants is lacking for this 
virus (only the release of HMGB1 has been documented), DCs 
exposed in vitro to measles-virus treated melanoma cells showed 
increased CD80 and CD86 expression levels (Table  1) (46). 
This resulted in the efficient priming of melanoma-specific cell 
killing by IFN-γ producing CD8+ T cells. Moreover, in terms of 
priming these melanoma-specific CTL responses, measles virus-
infected melanoma cells constituted more effective tumor lysates 
(also termed oncolysates) for loading of DCs than uninfected 
melanoma cell lysates (46). The DC stimulatory capacity of NDV-
derived oncolysates has already been demonstrated more than a 
decade ago by Schirrmacher et al. (47). DCs derived from breast 
cancer patients pulsed with NDV-oncolysates showed increased 
expression of costimulatory molecules in comparison to DCs 
loaded with tumor lysate from non-infected breast carcinoma 
cells (Table  1) (47). In addition, NDV-oncolysate-loaded DCs 
were more effective in stimulating bone-marrow-derived reactive 
memory T cells in vitro (47).
Oncolytic viruses hold great potential for application in 
ICD-based DC vaccines given their potential to elicit several 
ICD-related DAMPs. Furthermore, these viruses might directly 
affect DC maturation and activation through interaction with 
pathogen recognition receptors on the tumor cells. This way, bio-
logical oncolysates may render the use of an artificial maturation 
cocktail otiose. Unfortunately, there are no preclinical in vivo data 
available yet to evince the efficacy of DC vaccines loaded with 
immunogenic oncolysates (Table 2). Nevertheless, several studies 
have documented the beneficial effect of intratumoral applica-
tion of oncolytic viruses in combination with tumor-directed 
systemic DC vaccinations (72, 73). Very recently, Schirrmacher 
et  al. disclosed a case report of a breast cancer patient with 
liver metastasis that was treated with local hyperthermia, 
intravenously administered NDV, and subcutaneous vaccination 
with DCs loaded with NDV-infected breast cancer cells (onco-
lysate) (74). This combination therapy led to long-lasting tumor-
specific memory T cell responses and stable disease for more than 
66 months in this particular patient. The use of autologous DCs 
loaded with NDV-mediated oncolysate is licensed by the Paul 
Ehrlich Institute to the Immunologic-Oncologic Centre Cologne 
(IOZK) since May 2015.
Of note, in October 2015, the FDA approved the first oncolytic 
virus, Imlygic (a genetically modified live oncolytic herpes virus) 
for the treatment of melanoma lesions in the skin and lymph 
nodes. This FDA approval should facilitate the approval of other 
oncolytic viruses as well as the application of oncolysates in DC 
vaccine settings.
Photodynamic Therapy
Photodynamic therapy (PDT) is an established, minimally 
invasive anticancer treatment modality. It has a two-step mode of 
action involving the selective uptake of a photosensitizer by the 
tumor tissue, followed by its activation by light of a specific wave-
length. This activation results in the photochemical production of 
ROS in the presence of oxygen (129–131). One attractive feature 
of PDT is that the ROS-based oxidative stress originates in the 
particular subcellular location where the photosensitizer tends 
to accumulate, ultimately leading to the destruction of the tumor 
cell (132). PDT-based antitumor effects are multifactorial and 
depend on its abilities to damage the tumor vasculature, directly 
kill tumor cells, exert cytotoxic effects toward tumor-infiltrating 
immune cells, and recruit and activate immune cells that can 
initiate adaptive antitumor immune responses (131).
Increasing preclinical information is available regarding the 
impact of PDT on the immune system. Recent studies have 
demonstrated that PDT can effectively generate several DAMPs. 
HSP70, the best studied DAMP associated with PDT, is exposed 
on the surface of cancer cells treated with photofrin-PDT, 
5-Aminolevulinic acid (5-ALA)-PDT, and Foscan-PDT (51, 133, 
134). Of note, the uptake of tumor antigens and DC maturation 
induced by 5-ALA-PDT treated GBM spheroids were inhibited 
when HSP70 was blocked (133). Later, it was reported that 
photofrin-PDT also promotes the early/mid-apoptotic surface 
expression of CRT and the post-apoptotic release of HMGB1 
(52) (Table  1). Very recently, the DAMPs profile induced by 
Rose Bengal Acetate (RBAc)-based PDT was unraveled. RBAc-
photosensitized apoptotic/autophagic Hela cells were found to 
expose and/or release ATP, HSP70/90, HMGB1, and CRT (135). 
In terms of its immunogenicity, hypericin can be considered the 
best studied photosensitizer. Recently, hypericin-PDT became 
the first PDT modality capable of inducing prototypical ICD in 
cancer cells (20, 48, 49, 111). Hypericin localizes predominantly 
in the ER and upon irradiation it causes photo-oxidative ER 
stress, making hypericin-PDT the only known modality able to 
induce ICD through focused ROS-based ER stress (Type II ICD 
inducer), eventually culminating in mitochondrial apoptosis (49, 
136). In the pre-apoptotic stage, it induces the active emission of 
three crucial ICD-associated DAMPs, i.e., ecto-CRT, ecto-HSP, 
and secreted ATP (at a faster rate than what was previously 
published for these DAMPs), followed by the passive release of 
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HSP70 and HMGB1 (48, 49) (Table 1). Interestingly, this ICD-
subroutine was more effective in comparison to chemotherapy- 
or radiotherapy-induced ICD (48, 49).
The immunogenic features of Hyp-PDT–treated cancer 
cells have also been confirmed by ex vivo and in  vivo experi-
ments (Tables  1 and 2). Hyp-PDT-treated cancer cells form a 
productive interface with DCs in terms of phagocytosis (CRT-
dependent) and maturation (49) (Table  1). More specifically, 
the interacting DCs exhibit functional stimulation (NOhigh, 
IL-10absent, IL-6high, IL-1βhigh, and IL-12p70median) and phenotypic 
maturation (CD80high, CD83high, CD86high, and MHC-IIhigh) (49, 
53). Moreover, these immunogenic and fully mature DCs induce 
the clonal expansion of human IFN-γ producing CD4+ and CD8+ 
T cells (53, 54). Consequently, this in vitro antitumor immunity 
induced by Hyp-PDT-induced ICD led to the efficient rejection 
of murine tumors in vivo in the absence of any adjuvants (both in 
prophylactic and curative vaccination models) (49, 137). Besides 
hypericin-based PDT, photofrin-based PDT is to date the only 
PDT modality that is capable to fulfill this critical in vivo require-
ment for ICD characterization. Here, curative immunization with 
benzoporphyrin-based PDT-treated squamous cell carcinoma 
cells constituted a potent anticancer vaccine in this poorly immu-
nogenic model (56).
Importantly, inoculation of mature DCs in PDT-treated 
tumors resulted in the cytolytic activation of T cells and NK cells, 
leading to effective tumor eradication (75). Moreover, DC vac-
cines loaded with PDT-induced tumor lysates have been shown 
to cure fully established solid non-orthotopic tumors. This was 
associated with enhanced CTL responses and Th1 immunity 
(138) (Table 2). These data already suggest the clinical potential 
of PDT-based DC vaccines. In this regard, Hyp-PDT-induced 
ICD-based DC vaccines are currently being tested in a preclini-
cal model for ovarian cancer by Baert et al. (personal commu-
nication). Unfortunately, there are no clinical data available yet 
reporting the use of PDT-based DC vaccines.
Combinatorial Regimens
In DC vaccine settings, cancer cells are often not killed by a 
single treatment strategy but rather by a combination of treat-
ments. In some cases, the underlying rationale lies within the 
additive or even synergistic value of combining several moder-
ately immunogenic modalities. The combination of radiotherapy 
and heat shock has, for instance, been shown to induce higher 
levels of HSP70 in B16 melanoma cells than either therapy 
alone (16). In addition, a combination therapy consisting of 
heat shock, γ-irradiation, and UV irradiation has been shown 
to induce higher levels of ecto-CRT, ecto-HSP90, HMGB1, and 
ATP in comparison to either therapy alone or doxorubicin, a 
well-recognized inducer of ICD (57). Besides, the sequence of 
the applied methodologies seems to matter. The application of 
radiotherapy prior to freeze–thaw cycles was recently shown to 
negatively impacted the survival of high-grade glioma-bearing 
mice (in comparison to freeze–thaw cycles followed by X-ray 
irradiation) in the context of DC-based immunotherapy (18). 
A second rationale for combining several cell killing methodolo-
gies is to meet the clinical requirement of reaching 100% cancer 
cell death (14). Subcutaneous injection of irradiated tumor cells 
has, for instance, induced subcutaneous tumor growth in one 
glioblastoma patient (139). In general, most single treatment 
modalities discussed in this review cannot meet this require-
ment, postulating their combination with other (potentially less 
immunogenic) cell death modalities. In view of this, preclinical 
testing should always consider the most clinically relevant ver-
sion of the vaccine.
CONCLUDiNG ReMARKS
Triggering antitumor immune responses is an absolute require-
ment to tackle metastatic and diffusely infiltrating cancer cells 
that are resistant to standard-of-care therapeutic regimens. 
ICD-inducing modalities, such as PDT and radiotherapy, 
have been shown to be able to act as in situ vaccines capable 
of inducing immune responses that caused regression of distal 
untreated tumors. Exploiting these ICD inducers and other 
immunogenic modalities to obtain a highly immunogenic 
antigenic tumor cell cargo for loading DC vaccines is a highly 
promising application. In case of the two prominent ICD 
inducers, Hyp-PDT and HHP, preclinical studies evaluating 
this relatively new approach are underway and HHP-based 
DC vaccines are already undergoing clinical testing. In the pre-
clinical testing phase, more attention should be paid to some 
clinically driven considerations. First, one should consider 
the requirement of 100% mortality of the tumor cells before 
in vivo application. A second consideration from clinical prac-
tice (especially in multi-center clinical trials) is the fact that 
most tumor specimens arrive in the lab in a frozen state. This 
implies that a significant number of cells have already under-
gone non-immunogenic necrosis before the experimental cell 
killing strategies are applied. In case of ICD inducers, this 
could potentially hamper the immunogenicity of the tumor 
cells as these modalities mainly rely on active danger signaling 
pathways. Finally, for a more clinically relevant evaluation of 
the effect of immunogenic DC vaccines on tumor cell stromal 
interactions, orthotopic tumor inoculation should be applied. 
As tumor cells are implanted in the anatomically appropriate 
location, orthotopic tumors reflect the clinical situation (e.g., 
the tumor microenvironment) much better than conventional 
subcutaneous non-orthotopic models.
Even the most potent active immunotherapeutic strategies 
such as (ICD-based) DC vaccines will, however, be hampered 
by the presence of immunomodulatory immune checkpoint 
molecules (such as PD-1 and CTLA-4) that inhibit cytotoxic 
immune responses or even induce immune tolerance. The devel-
opment of drugs that can unleash these inhibitory molecules has 
become one of the most active areas in oncology. This creates the 
opportunity to combine checkpoint inhibitors with DC-based 
immunotherapy. The synergistic action of a CTLA-4 block-
ing Ab (tremelimumab) in combination with DC therapy has 
already been demonstrated in advanced melanoma patients and 
several other trials evaluating this approach are on the horizon 
(6, 140, 141).
We believe that the specialty of DC-based immunotherapy is 
considerably moving forward by focusing on developing more 
immunogenic Th1-driving vaccines, such as ICD-based DC 
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vaccines. Moreover, the combination of ICD-based DC vaccines 
with checkpoint inhibitors or other drugs that can inhibit the 
severe tumor-induced immune suppression might be able to 
reveal the full efficacy of DC-based immunotherapy for cancer.
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